The process of inserting, deleting, modifying, or replacing DNA bases in an organism is known as genome engineering. Ex-Vivo Gene Therapy and In-Vivo Gene Therapy are the two types of gene therapy. Ex-vivo gene therapy involves transferring genes to cultured cells and subsequently reintroducing them into the patient, whereas in-vivo gene therapy involves delivering genes directly to cells in a specific tissue.
The pharmaceutical businesses category accounted for a considerable part of the Genome Engineering Market in 2019. This market domination can be linked to the increasing number of research activities as a result of the rising number of infectious illness cases and cancer patients. These research and development initiatives are being carried out in order to develop an antidote for cancer and other infectious diseases. This factor is expected to increase demand for genome engineering in biotechnology and pharmaceutical firms in the industry.
Read more @ https://cmiaspireblog.blogspot.com/2022/02/genome-engineering-market-size-share.html
